#hepcidin

[etlu-yume]

I really ought to finish these damn Transferrin Saturation paper notes but I'm struggling with the line-by-line horror stories of how fucked up it is.

Like phew I don't even know what's worse:

• Transferrin Saturation as an indicator of Hepcidin production (oop)

• >50% Transferrin Saturation exposure associated with joint symptoms

• High Transferrin Saturation (>50%) also associated with the appearance of NTBI (Non-transferrin bound iron), which is likely linked to things like *organ damage*

• Therapeutic Phlebotomy treatment linked to an INCREASED iron absorption after procedures because (somehow. I haven't found exactly HOW yet) it decreases Hepcidin production.

It's such a fucking hot mess like what do we even DO with this information??? There's no hepcidin synthetics from a few (admittedly quick) googles (I *did* check the clinical trials website and nothing of interest/help). The paper in question talks about how a Melbourne study suggests that it may be more beneficial to *NOT* treat mild cases of iron overload. Which I find wild because the same paper also points out that a low ferritin does not mean you have a low transferrin saturation, and it's exposure to a high TS% over a long period of time that seems to be associated with worsening symptoms (particularly joint pain, ability to do work, athletic ability, and libido).

From my brief googles, there's no easy lab tests for Hepcidin. There's no easy lab tests for NTBI. These are things that could be doing who-knows-what and we can't even tell.

Add to it the whole Estradiol/Hepcidin link and it just all is an absolutely hot mess and do not like the implications of where this leads nor the fact that it seems very few people in research world have looked at this. (I'm not surprised. I'm not fucking surprised. They love to run with the myth that women with haemochromatosis are protected by their periods. In the words of a specialist I absolutely loathed, "you're self medicating with periods". Yeah. Sure. Tell that to my 18 year old self. Tell that to anyone who either knowingly or unknowingly is taking a Contraceptive Pill that has iron tablets instead of sugar placebos. [Because I only just found out THAT is a thing. I was always so worried about what's in the hormone tablets, but this was a whole new level of 'wot'].)

I'm rambling because I keep stopping every couple of sentences. This paper goes hard. Sure it's not perfect and there's a lot of unanswered questions too but there's plenty of food for thought and ooooh boy I'm sorry Dr Haemotologist Sir, it's gonna be one hell of an introduction session.

[ubuntu-village]

How Hepcidin Affects Psoriasis and Your Skin

If you’ve ever experienced psoriasis or know someone who has, you understand how challenging it can be to manage this skin condition. Psoriasis causes skin cells to multiply too quickly, leading to thick, red patches that are often itchy or painful. But did you know that researchers have been exploring the role of a hormone called hepcidin in psoriasis? Hepcidin is a key player in regulating iron…

How Hepcidin Affects Psoriasis and Your Skin

[etlu-yume]

today's "light reading"; Hepcidin Therapeutics

there's 9 pages (N I N E) of references on this paper, good lord. (That's still better than all 30 pages to try and wade through but holy moly that reference list)

[mega-prajakta-123]

Hepcidin Market 2019 Global Industry Size, Demand, Growth Analysis, Share, Revenue and Forecast to 2024

Oct 16, 2019 (The Expresswire) -- Global Hepcidin Market by Manufactures, Types, Applications and Forecast 2019-2024 Global “Hepcidin Market” 2019-2024...

[reportsandmarkets]

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Pipeline Review, H2 2017

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Pipeline Review, H2 2017 Access Full Report: https://www.reportsandmarkets.com/reports/hepcidin-liver-expressed-antimicrobial-peptide-1-h2-2017-1712841 Summary According to the recently published report ‘Hepcidin – Pipeline Review, H2 2017’; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative…

View On WordPress

[helloancycruzworld]

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Pipeline Review H1 2017 Research Report Now Available at Orbis Research

Description:

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Hematological Disorders, Genetic Disorders, Immunology, Oncology and Toxicology which include indications Hemochromatosis, Thalassemia, Acute Inflammation, Anemia, Anemia in Chronic Kidney Disease (Renal Anemia), Anemia of Chronic Disease, Chemotherapy Induced Anemia, Iron Deficiency Anemia, Polycythemia Vera and Sickle Cell Disease.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310026 .

The latest report Hepcidin - Pipeline Review, H1 2017, outlays comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope - The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)targeted therapeutics and enlists all their major and minor projects - The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Browse the full report @ http://www.orbisresearch.com/reports/index/hepcidin-liver-expressed-antimicrobial-peptide-1-or-putative-liver-tumor-regressor-or-hamp-pipeline-review-h1-2017 .

Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned Daiichi Sankyo Company Ltd Noxxon Pharma AG Pieris Pharmaceuticals Inc Protagonist Therapeutics Inc

Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310026 .

For any enquires before buying, connect with us @ [email protected]

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No.: [phone]; [phone]

For more information contact [email protected]